Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus and pertussis vaccine
- Development stage
- Approved
- Lead developer
- AIM Persistence Biopharmaceutical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The diphtheria, tetanus, and pertussis (DTcP) vaccine developed by Zhejiang Weixin Biological Pharmaceutical (a subsidiary of AIM Vaccine) is a genetically engineered, three-component acellular combination vaccine. It is designed for the primary immunization of infants to prevent diphtheria, tetanus, and whooping cough (pertussis). Unlike traditional whole-cell vaccines, this acellular formulation utilizes a gene expression-based purification and detoxification process, making it the first genetically engineered three-component pertussis vaccine in China. The vaccine targets the diphtheria toxin, tetanus toxin, and specific pertussis antigens. Clinical data from Phase III trials indicate a favorable safety profile and superior immunogenicity against pertussis compared to standard combination vaccines.
- Other names
- DTcPAcellular component pertussis vaccineDTP vaccineDiphtheria-tetanus-acellular pertussis vaccine
02
Targets
PRN (Pertactin)FIM (Bordetella pertussis fimbriae)Diphtheria toxinFHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on diphtheria, tetanus and pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus and pertussis vaccine.